A proposal for a serology-based approach to membranous nephropathy

Journal of the American Society of Nephrology

Volumn 28, Issue 2, 2017, Pages 421-430

  De Vriese, An S ^a   Glassock, Richard J ^b   Nath, Karl A ^c   Sethi, Sanjeev ^c   Fervenza, Fernando C ^c  

^a Department of Internal Medicine   (Belgium)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

M TYPE PHOSPHOLIPASE A2 RECEPTOR 1; PHOSPHOLIPASE A2 RECEPTOR; PROTEIN ANTIBODY; THROMBOSPONDIN; THROMBOSPONDIN TYPE 1 DOMAIN CONTAINING 7A PROTEIN; UNCLASSIFIED DRUG; AUTOANTIBODY; PLA2R1 PROTEIN, HUMAN;

ALGORITHM; ANTIBODY TITER; CONSERVATIVE TREATMENT; DIAGNOSTIC VALUE; HUMAN; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; MEMBRANOUS GLOMERULONEPHRITIS; NEPHROTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; RECURRENT DISEASE; REVIEW; SEROLOGY; WESTERN BLOTTING; BLOOD; GLOMERULONEPHRITIS, MEMBRANOUS; IMMUNOLOGY;

ALGORITHMS; AUTOANTIBODIES; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; KIDNEY TRANSPLANTATION; PROGNOSIS; RECEPTORS, PHOSPHOLIPASE A2; SEROLOGIC TESTS;

EID: 85019752295     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2016070776     Document Type: Review

References (68)

1. Beck LH Jr., Bonegio RG , Lambeau G, Beck DM, Powell DW, Cummins TD, Klein JB, Salant DJ: M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 361: 11-21, 2009
2. Tomas NM, Beck LH Jr., Meyer-Schwesinger C, Seitz-Polski B, Ma H, Zahner G, Dolla G, Hoxha E, Helmchen U, Dabert-Gay AS, Debayle D, Merchant M, Klein J, Salant DJ, Stahl RA, Lambeau G: Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med 371: 2277-2287, 2014
3. Tomas NM, Hoxha E, Reinicke AT, Fester L, Helmchen U, Gerth J, Bachmann F, Budde K, Koch-Nolte F, Zahner G, Rune G, Lambeau G, Meyer-Schwesinger C, Stahl RA: Autoantibodies against thrombospondin type 1 domain-containing 7A induce membranous nephropathy. J Clin Invest 126: 2519-2532, 2016
4. Larsen CP, Cossey LN, Beck LH: THSD7A staining of membranous glomerulopathy in clinical practice reveals cases with dual autoantibody positivity. Mod Pathol 29: 421-426, 2016
5. Debiec H, Lefeu F, Kemper MJ, Niaudet P, Deschênes G, Remuzzi G, Ulinski T, Ronco P: Early-childhood membranous nephropathy due to cationic bovine serum albumin. N Engl J Med 364: 2101-2110, 2011
6. Glassock RJ: Human idiopathic membranous nephropathy-a mystery solved?. N Engl J Med 361: 81-83, 2009
7. Beck LH Jr., Salant DJ: Membranous nephropathy: Frommodels to man. JClin Invest 124: 2307-2314, 2014
8. Kidney disease: Improving GlobalOutcomes (KDIGO) Glomerulonephritis Work Group: KDIGO clinical practice guideline for glomerulonephritis. Kidney Int 2: 139-274, 2012
9. Glassock RJ: Antiphospholipase A2 receptor autoantibody guided diagnosis and treatment of membranous nephropathy: A new personalized medical approach. Clin J Am Soc Nephrol 9: 1341-1343, 2014
10. Behnert A, Schiffer M, Müller-Deile J, Beck LH Jr., Mahler M, Fritzler MJ: Antiphospholipase A2 receptor autoantibodies: A comparison of three different immunoassays for the diagnosis of idiopathic membranous nephropathy. J Immunol Res 2014: 143274, 2014
11. Timmermans SA, Damoiseaux JG, Heerings-Rewinkel PT, Ayalon R, Beck LH Jr., Schlumberger W, Salant DJ, van Paassen P, Tervaert JW; Limburg Renal Registry: Evaluation of anti-PLA2R1 as measured by a novel ELISA in patients with idiopathic membranous nephropathy: A cohort study. Am J Clin Pathol 142: 29-34, 2014
12. Hoxha E, Beck LH Jr., Wiech T, Tomas NM, Probst C, Mindorf S, Meyer-Schwesinger C, Zahner G, Stahl PR, Schöpper R, Panzer U, Harendza S, Helmchen U, Salant DJ, Stahl RA: An indirect immunofluorescencemethod facilitates detection of thrombospondin type 1 domain-containing 7A-specific antibodies in membranous nephropathy [published online ahead of print July 19, 2016]. J Am Soc Nephrol
13. Hoxha E, Kneißler U, Stege G, Zahner G, Thiele I, Panzer U, Harendza S, Helmchen UM, Stahl RA: Enhanced expression of the M-type phospholipaseA2 receptor inglomeruli correlates with serum receptor antibodies in primary membranous nephropathy. Kidney Int 82: 797-804, 2012
14. Debiec H, Ronco P: PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy. N Engl J Med 364: 689-690, 2011
15. Svobodova B, Honsova E, Ronco P, Tesar V, Debiec H: Kidney biopsy is a sensitive tool for retrospective diagnosis of PLA2R-related membranous nephropathy. Nephrol Dial Transplant 28: 1839-1844, 2013
16. Ramachandran R, Kumar V, Kumar A, Yadav AK, Nada R, Kumar H, Kumar V, Rathi M, Kohli HS, Gupta KL, Sakhuja V, Jha V: PLA2R antibodies, glomerular PLA2R deposits and variations in PLA2R1 and HLA-DQA1 genes in primary membranous nephropathy in South Asians. Nephrol Dial Transplant 31: 1486-1493, 2016
17. Ronco P, Debiec H: Pathophysiological advances in membranous nephropathy: Time for a shift in patient's care. Lancet 385: 1983-1992, 2015
18. Du Y, Li J, He F, Lv Y, Liu W, Wu P, Huang J, Wei S, Gao H: The diagnosis accuracy of PLA2R-AB in the diagnosis of idiopathic membranous nephropathy: A meta-analysis. PLoS One 9: E104936, 2014
19. Dai H, Zhang H, He Y: Diagnostic accuracy of PLA2R autoantibodies and glomerular staining for the differentiation of idiopathic and secondary membranous nephropathy: An updated meta-analysis. Sci Rep 5: 8803, 2015
20. Fervenza FC, Glassock RJ, Bleyer AJ: American Society of Nephrology quiz and questionnaire 2012: Glomerulonephritis. Clin J Am Soc Nephrol 8: 1460-1465, 2013
21. van de Logt AE, Hofstra JM, Wetzels JF: Serum anti-PLA2R antibodies can be initially absent in idiopathic membranous nephropathy: Seroconversion after prolonged followup. Kidney Int 87: 1263-1264, 2015
22. Ramachandran R, Kumar V, Nada R, Jha V: Serial monitoring of anti-PLA2R in initial PLA2R-negative patients with primary membranous nephropathy. Kidney Int 88: 1198-1199, 2015
23. Hoxha E, Harendza S, Zahner G, Panzer U, Steinmetz O, Fechner K, Helmchen U, Stahl RA: An immunofluorescence test for phospholipase-A2-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis. Nephrol Dial Transplant 26: 2526-2532, 2011
24. Gunnarsson I, Schlumberger W, Rönnelid J: Antibodies to M-type phospholipase A2 receptor (PLA2R) and membranous lupus nephritis. Am J Kidney Dis 59: 585-586, 2012
25. Akiyama S, Akiyama M, Imai E, Ozaki T, Matsuo S, Maruyama S: Prevalence of antiphospholipase A2 receptor antibodies in Japanese patients with membranous nephropathy. Clin Exp Nephrol 19: 653-660, 2015
26. Kim YG, Choi YW, KimSY, Moon JY, IhmCG, Lee TW, Jeong KH, Yang SH, Kim YS, Oh YJ, Lee SH: Anti-phospholipase A2 receptor antibody as prognostic indicator in idiopathic membranous nephropathy. Am J Nephrol 42: 250-257, 2015
27. QinW, Beck LH Jr., Zeng C, Chen Z, Li S, Zuo K, Salant DJ, Liu Z: Anti-phospholipase A2 receptor antibody in membranous nephropathy. J Am Soc Nephrol 22: 1137-1143, 2011
28. Larsen CP, Messias NC, Silva FG, Messias E, Walker PD: Determination of primary versus secondary membranous glomerulopathy utilizing phospholipase A2 receptor staining in renal biopsies. Mod Pathol 26: 709-715, 2013
29. Timmermans SA, Ayalon R, van Paassen P, Beck LH Jr., van Rie H, Wirtz JJ, VerseputGH, Frenken LA, Salant DJ, Cohen Tervaert JW; Limburg Renal Registry: Anti-phospholipase A2 receptor antibodies and malignancy in membranous nephropathy. Am J Kidney Dis 62: 1223-1225, 2013
30. Oh YJ, Yang SH, Kim DK, Kang SW, Kim YS: Autoantibodies against phospholipase A2 receptor in Korean patients with membranous nephropathy. PLoS One 8: E62151, 2013
31. Xie Q, Li Y, Xue J, Xiong Z, Wang L, Sun Z, Ren Y, Zhu X, Hao CM: Renal phospholipase A2 receptor in hepatitis B virus-associated membranous nephropathy. Am J Nephrol 41: 345-353, 2015
32. Iwakura T, Ohashi N, Kato A, Baba S, Yasuda H: Prevalence of enhanced granular expression of thrombospondin type-1 domaincontaining 7A in the glomeruli of Japanese patients with idiopathic membranous nephropathy. PLoS One 10: E0138841, 2015
33. Wei SY, Wang YX, Li JS, Zhao SL, Diao TT, Wang Y, Wang C, Qin Y, Cao Y, Wei Q, Li B: Serum anti-PLA2R antibody predicts treatment outcome in idiopathic membranous nephropathy. Am J Nephrol 43: 129-140, 2016
34. Stehlé T, Audard V, Ronco P, Debiec H: Phospholipase A2 receptor and sarcoidosisassociated membranous nephropathy. Nephrol Dial Transplant 30: 1047-1050, 2015
35. Hoxha E, Wiech T, Stahl PR, ZahnerG, Tomas NM, Meyer-Schwesinger C, WenzelU, Janneck M, Steinmetz OM, Panzer U, Harendza S, Stahl RA: A mechanism for cancer-associated membranous nephropathy. N Engl J Med 374: 1995-1996, 2016
36. Rodriguez EF, Nasr SH, Larsen CP, Sethi S, Fidler ME, Cornell LD: Membranous nephropathy with crescents: A series of 19 cases. AmJ Kidney Dis 64: 66-73, 2014
37. Cattran DC, Pei Y, Greenwood CM, Ponticelli C, Passerini P, Honkanen E: Validation of a predictive model of idiopathic membranous nephropathy: Its clinical and research implications. Kidney Int 51: 901-907, 1997
38. Polanco N, Gutiérrez E, Covarsí A, Ariza F, Carreño A, Vigil A, Baltar J, Fernández-Fresnedo G, Martín C, Pons S, Lorenzo D, Bernis C, Arrizabalaga P, Fernández-Juárez G, Barrio V, Sierra M, Castellanos I, Espinosa M, Rivera F, Oliet A, Fernández-Vega F, Praga M; Grupo de Estudio de las Enfermedades Glomerulares de la Sociedad Española de Nefrología: Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol 21: 697-704, 2010
39. Hofstra JM, Beck LH Jr., Beck DM, Wetzels JF, Salant DJ: Anti-phospholipase A2 receptor antibodies correlate with clinical status in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 6: 1286-1291, 2011
40. Hofstra JM, Debiec H, Short CD, Pellé T, Kleta R, Mathieson PW, Ronco P, Brenchley PE, Wetzels JF: Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy. J Am Soc Nephrol 23: 1735-1743, 2012
41. Murtas C, Bruschi M, Candiano G, Moroni G, Magistroni R, Magnano A, Bruno F, Radice A, Furci L, Argentiero L, Carnevali ML, Messa P, Scolari F, Sinico RA, Gesualdo L, Fervenza FC, Allegri L, Ravani P, Ghiggeri GM: Coexistence of different circulating anti-podocyte antibodies in membranous nephropathy. Clin J Am Soc Nephrol 7: 1394-1400, 2012
42. Guerry MJ, Vanhille P, Ronco P, Debiec H: Serum anti-PLA2R antibodies may be present before clinical manifestations of membranous nephropathy. Kidney Int 89: 1399, 2016
43. Timmermans SA, Abdul Hamid MA, Cohen Tervaert JW, Damoiseaux JG, van Paassen P; Limburg Renal Registry: Anti-PLA2R antibodies as a prognostic factor in PLA2Rrelated membranous nephropathy. Am J Nephrol 42: 70-77, 2015
44. Hoxha E, Harendza S, Pinnschmidt H, Panzer U, Stahl RA: PLA2R antibody levels and clinical outcome in patients with membranous nephropathy and non-nephrotic range proteinuria under treatment with inhibitors of the renin-angiotensin system. PLoS One 9: E110681, 2014
45. Kanigicherla D, Gummadova J, McKenzie EA, Roberts SA, Harris S, Nikam M, Poulton K, McWilliam L, Short CD, Venning M, Brenchley PE: Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy. Kidney Int 83: 940-948, 2013
46. Hoxha E, Harendza S, Pinnschmidt H, Panzer U, Stahl RA: M-type phospholipase A2 receptor autoantibodies and renal function in patients with primary membranous nephropathy. Clin J Am Soc Nephrol 9: 1883-1890, 2014
47. Radice A, Trezzi B, Maggiore U, Pregnolato F, Stellato T, Napodano P, Rolla D, Pesce G, D'Amico M, Santoro D, Londrino F, Ravera F, Ortisi G, Sinico RA: Clinical usefulness of autoantibodies to M-type phospholipase A2 receptor (PLA2R) for monitoring disease activity in idiopathic membranous nephropathy (IMN). Autoimmun Rev 15: 146-154, 2016
48. Hoxha E, Thiele I, Zahner G, Panzer U, Harendza S, Stahl RA: Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy. J Am Soc Nephrol 25: 1357-1366, 2014
49. Seitz-Polski B, Dolla G, Payré C, Girard CA, Polidori J, Zorzi K, Birgy-Barelli E, Jullien P, Courivaud C, Krummel T, Benzaken S, Bernard G, Burtey S, Mariat C, Esnault VL, Lambeau G: Epitope spreading of autoantibody response to PLA2R associates with poor prognosis in membranous nephropathy. J Am Soc Nephrol 27: 1517-1533, 2016
50. Hoxha E, Harendza S, Pinnschmidt HO, Tomas NM, Helmchen U, Panzer U, Stahl RA: Spontaneous remission of proteinuria is a frequent event in phospholipase A2 receptor antibody-negative patients with membranous nephropathy. Nephrol Dial Transplant 30: 1862-1869, 2015
51. Hofstra JM, Fervenza FC, Wetzels JF: Treatment of idiopathic membranous nephropathy. Nat Rev Nephrol 9: 443-458, 2013
52. Kanigicherla DA, Short CD, Roberts SA, Hamilton P, Nikam M, Harris S, Brenchley PE, VenningMC: Long-termoutcomesofpersistent disease and relapse in primary membranous nephropathy [published online ahead of print January 13, 2016]. Nephrol Dial Transplant
53. Ruggenenti P, Debiec H, Ruggiero B, Chianca A, Pellé T, Gaspari F, Suardi F, Gagliardini E, Orisio S, Benigni A, Ronco P, Remuzzi G: Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy. J Am Soc Nephrol 26: 2545-2558, 2015
54. Bech AP, Hofstra JM, Brenchley PE, Wetzels JF: Association of anti-PLA2R antibodieswith outcomes after immunosuppressive therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 9: 1386-1392, 2014
55. Medrano AS, Escalante EJ, Cáceres CC, Pamplona IA, Allende MT, Terrades NR, Carmeno NV, Roldán EO, Agudelo KV, Vasquez JJ: Prognostic value of the dynamics of M-type phospholipase A2 receptor antibody titers in patients with idiopathic membranous nephropathy treated with two different immunosuppression regimens. Biomarkers 20: 77-83, 2015
56. Beck LH Jr., Fervenza FC, Beck DM, Bonegio RG, Malik FA, Erickson SB, Cosio FG, Cattran DC, Salant DJ: Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol 22: 1543-1550, 2011
57. Müller-Deile J, Schiffer L, Hiss M, Haller H, Schiffer M: A new rescue regimen with plasma exchange and rituximab in high-risk membranous glomerulonephritis. Eur J Clin Invest 45: 1260-1269, 2015
58. Grupper A, Cornell LD, Fervenza FC, Beck LH Jr., Lorenz E, Cosio FG: Recurrent membranous nephropathy after kidney transplantation: Treatment and long-term implications [published online ahead of print December 30, 2015]. Transplantation 2015
59. Dabade TS, Grande JP, Norby SM, Fervenza FC, Cosio FG: Recurrent idiopathic membranous nephropathy after kidney transplantation: A surveillance biopsy study. Am J Transplant 8: 1318-1322, 2008
60. Debiec H, Martin L, Jouanneau C, Dautin G, Mesnard L, Rondeau E, Mousson C, Ronco P: Autoantibodies specific for the phospholipase A2 receptor in recurrent and de novo membranous nephropathy. Am J Transplant 11: 2144-2152, 2011
61. Larsen CP, Walker PD: Phospholipase A2 receptor (PLA2R) staining is useful in the determination of de novo versus recurrent membranous glomerulopathy. Transplantation 95: 1259-1262, 2013
62. Quintana LF, Blasco M, Seras M, Pérez NS, López-HoyosM, Villarroel P, Rodrigo E, Viñas O, Ercilla G, Diekmann F, Gómez-Roman JJ, Fernandez-Fresnedo G, Oppenheimer F, Arias M, Campistol JM: Antiphospholipase A2 receptor antibody levels predict the risk of posttransplantation recurrence of membranous nephropathy. Transplantation 99: 1709-1714, 2015
63. Gupta G, Fattah H, Ayalon R, Kidd J, Gehr T, Quintana LF, Kimball P, Sadruddin S, Massey HD, Kumar D, King AL, Beck LH Jr.: Pretransplant phospholipase A2 receptor autoantibody concentration is associated with clinically significant recurrence of membranous nephropathy post-kidney transplantation. Clin Transplant 30: 461-469, 2016
64. Kattah A, Ayalon R, Beck LH Jr., Sethi S, Sandor DG, Cosio FG, Gandhi MJ, Lorenz EC, SalantDJ, Fervenza FC: Anti-phospholipase A2 receptor antibodies in recurrent membranous nephropathy. Am J Transplant 15: 1349-1359, 2015
65. Seitz-Polski B, Payré C, Ambrosetti D, Albano L, Cassuto-Viguier E, Berguignat M, Jeribi A, Thouret MC, Bernard G, Benzaken S, Lambeau G, Esnault VL: Prediction of membranous nephropathy recurrence after transplantation by monitoring of anti-PLA2R1 (M-type phospholipase A2 receptor) autoantibodies: A case series of 15 patients. Nephrol Dial Transplant 29: 2334-2342, 2014
66. Kattah AG, Alexander MP, Angioi A, De Vriese AS, Sethi S, Cosio FG, Lorenz EC, Cornell LD, Fervenza FC: Temporal IgG Subtype changes in recurrent idiopathic membranous nephropathy. Am J Transplant 16: 2964-72, 2016
67. Fervenza FC, Abraham RS, Erickson SB, Irazabal MV, Eirin A, Specks U, Nachman PH, Bergstralh EJ, Leung N, Cosio FG, Hogan MC, Dillon JJ, Hickson LJ, Li X, Cattran DC; Mayo Nephrology Collaborative Group: Rituximab therapy in idiopathic membranous nephropathy: A 2-year study. Clin J Am Soc Nephrol 5: 2188-2198, 2010
68. Specks U, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Fessler BJ, Ding L, Viviano L, TchaoNK, Phippard DJ, Asare AL, LimN, Ikle D, Jepson B, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh K, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Mueller M, Sejismundo LP, Mieras K, Stone JH: Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363: 417-427, 2013